SOURCE: SK3 Group, Inc.

February 14, 2014 10:50 ET

SK3 Group's (OTC PINK: SKTO) Medical Greens Is Pleased to Announce That the First Bottles of Dharmanol™ Are Shipping and Will Be Immediately Available on www.pharmajanes.com Among Other Places

LOS ANGELES, CA--(Marketwired - Feb 14, 2014) - SK3 Group, Inc's (OTC Pink: SKTO) subsidiary Medical Greens is pleased to announce that the first bottles of Dharmanol™ Whole Plant tablets, for which Medical Greens has the exclusive license, are shipping today. Dharmanol™ is a medical cannabis-based supplement that contains all of the natural elements of the cannabis/hemp plant that are thought to promote healing, with the exception of THC, the molecule which is responsible for the psychoactive effect -- or "high" -- of marijuana.

Dharmanol™, developed by David Hoye and Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories, contains under .03% THC, less than many hemp-based health products that are sold at stores such as Costco and Walgreens. But it contains 10 mg. of the non-psychoactive phyto-cannabinoids that are present in hemp/cannabis, and are thought to contribute to the myriad of mechanisms that many university-level scientific studies have shown to be responsible for the remarkable healing power of medical marijuana.

Dharmanol™ tablets will be available soon in California through AEGY's www.pharmajanes.com delivery service and select medicinal marijuana dispensaries.

Dharmanol™ is sold in a bottle of 8 tablets. The suggested retail price for a bottle is $25.00. Each tablet contains 5 mg. cannabidiol (CBD), 5 mg. of non-psychoactive mixed carboxylates of the primary cannabinoids, 5 mg. of mixed separated terpenes and terpenoids of cannabis/hemp, 25 mg. of organic cold-pressed hemp oil, and 25 mg. of vitamin C (ascorbic acid as a preservative).

Dharmanol Citrolene™ will be released shortly. This formulation combines the phyto-cannabinoid formula found in Dharmanol™ with a substantial dose of the terpene d-Limonene. D-Limonene is found in cannabis/hemp, but also present in the rinds of certain citrus fruits. D-Limonene has been shown to bind with the same receptors as benzodiazapines such as Valium and Xanax, producing a pronounced relaxing and anti-spasmodic effect, without the negative side effects that many attribute to the synthetic pharmaceuticals.

"We are pleased to be able to start delivering this important product to market through our distribution network of dispensaries and our related web-based delivery service www.pharmajanes.com," said Artemus Mayor, President of SK3 Group, Inc. "These products are industry leading and will allow us to deliver the health benefits of medical marijuana to more patients who will not have to worry about feeling 'high' after their use. These products will contribute directly to our topline revenue growth."

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information